Breast cancer surgery is going to be a relevant specialty involved in the multidisciplinary disease management, finalized to guarantee high performances on mortality reduction together with a quality-of-life improvement. The intellectual architecture of this field is characterized by its inclination to respect, sharing, empathy and scientific knowledge that can make it a high model of medical culture. In this context, oncoplastic breast conserving surgery is identified by special aesthetic sensitivities, as well as creativity and innovation. Knowing how to reshape the gland and fill the gaps, planning the targeted exeresis design, while anticipating the final outcome, respecting symmetries and ensuring first of all oncological safety, are the new skills that are required to the breast surgeon. Several tecniques could provide a refined surgical treatment but always challenging according to anatomical findings and patient expectations, as a systematic process of self-critical reflection, with the purpose to optimize criteria for improving therapeutic results.

Download full-text PDF

Source
http://dx.doi.org/10.23736/S2724-5691.21.08976-0DOI Listing

Publication Analysis

Top Keywords

breast conserving
8
conserving surgery
8
update oncoplastic
4
oncoplastic techniques
4
breast
4
techniques breast
4
surgery algorithms
4
algorithms predictable
4
predictable custom-made
4
custom-made reconstructions
4

Similar Publications

Breast cancer is the most common cancer type among women according to the World Health Organization data. While breast-conserving surgery has been increasingly performed in patients with early-stage breast cancer, unilateral or bilateral mastectomy is still performed in many patients. With the changes in mastectomy techniques and the development of breast reconstruction techniques over the years, today the aim of breast reconstruction is to create breast tissue in a shape and symmetry that will correct the anatomical defect that occurs after mastectomy, without affecting the patient's oncological treatment.

View Article and Find Full Text PDF

Assessing fetal radiation dose from iodine-125 seeds in pregnant breast cancer patients: an updated model.

Phys Med Biol

January 2025

Department of Medical Physics, Jeroen Bosch Ziekenhuis, Henri Dunantstraat 1, 's-Hertogenbosch, 5223GZ, NETHERLANDS.

The treatment of breast cancer during pregnancy requires careful consideration of consequences for both maternal and fetal health. In non-pregnant patients, the use of radioactive iodine-125 (125I)-seeds is standard practice for localising non-palpable breast tumors before breast-conserving surgery. However, the use of 125I-seeds in pregnant patients has been avoided due to concerns about fetal radiation exposure.

View Article and Find Full Text PDF

Background: Breast cancer patients experience acute radiation dermatitis (ARD) during radiation therapy (RT). This study investigated the prophylactic effect of a newly developed xenogeneic platelet-rich plasma (PRP) lotion on ARD for breast cancer patients.

Methods: This study enrolled patients with ductal carcinoma in situ and early-stage invasive breast cancers after breast-conserving surgery.

View Article and Find Full Text PDF

Transferrin Disassociates TCR from CD3 Signaling Apparatus to Promote Metastasis.

Research (Wash D C)

January 2025

Key Laboratory of Genetic Evolution & Animal Models, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Sino-African Joint Research Center, and New Cornerstone Science Laboratory, Kunming Institute of Zoology, The Chinese Academy of Sciences, Kunming, Yunnan 650201, China.

Immune recognition and activation by the peptide-laden major histocompatibility complex-T cell receptor (TCR)-CD3 complex is essential for anti-tumor immunity. Tumors may escape immune surveillance by dissembling the complex. Here, we report that transferrin, which is overexpressed in patients with liver metastasis, disassociates TCR from the CD3 signaling apparatus by targeting the constant domain (CD) of T cell receptor α (TCRα), consequently suppresses T cell activation, and inhibits anti-metastatic and anti-tumor immunity.

View Article and Find Full Text PDF

Background: Male breast cancer (MBC) is a rare disease, accounting for 1% of all breast cancers diagnosed in the United States. The rarity of MBC has limited the development of treatment algorithms specific to men. Thus, the standard of care has been mastectomy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!